AOC-1020 + Placebo
Phase 3RecruitingDevelopment Stage
Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Jun 10, 2025 → Jul 1, 2028
About AOC-1020 + Placebo
AOC-1020 + Placebo is a phase 3 stage product being developed by Avidity Biosciences for Facioscapulohumeral Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07038200. Target conditions include Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07038200 | Phase 3 | Recruiting |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 + ACE-083 or placebo | Merck | Phase 2 | 52 |
| ACE-083 | Merck | Phase 2 | 52 |
| Placebo + RO7204239 | Roche | Phase 2 | 52 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 49 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 69 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |